Previous Article | Next Article ![]()
Infect. Immun., 04 1997, 1258-1266, Vol 65, No. 4
D Su, RI Roth, M Yoshida and J Levin
Cell-free hemoglobin (Hb) is being developed as an erythrocyte substitute.
We have previously demonstrated that cell-free Hb is an endotoxin-binding
protein which disaggregates endotoxin and subsequently increases the
biological activity of endotoxin in several in vitro assays. Because much
of the morbidity and mortality associated with gram-negative bacterial
infection is the result of pathophysiologic responses to bacterial
lipopolysaccharide (LPS; endotoxin), we studied the effect of Hb on
LPS-mediated mortality. Hb infused intravenously into mice before,
coincident with, or after intraperitoneal LPS injection substantially
increased LPS-related mortality from <5% to 50 to 70% 24 h after
administration of LPS and from 50% to 60 to 90% at 48 h. Enhanced mortality
was observed over a range of doses of injected LPS. At a given LPS dose,
enhancement of mortality was shown to be dependent on the dose of Hb
administered. Unmodified native human Hb, alpha-alpha-cross-linked human
Hb, and beta- beta-cross-linked human or bovine Hb all were shown to
enhance LPS- mediated mortality. Depressed reticuloendothelial cell
function may have contributed to the enhanced mortality from LPS in the
presence of Hb. Therefore, Hb-based blood substitutes, which are currently
undergoing clinical trials, may intensify the potentially fatal effects of
the sepsis syndrome in patients with trauma, infection, or hypotension who
receive Hb for erythrocyte replacement.
Copyright © 1997, American Society for Microbiology
Hemoglobin increases mortality from bacterial endotoxin
Department of Laboratory Medicine, University of California School of Medicine, Department of Veterans Affairs Medical Center, San Francisco 94121, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|